Cargando…
The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
Primary mediastinal large B-cell lymphoma (PMBCL) is a subtype of diffuse large B-cell lymphoma (DLBCL). PMBCL comprises approximately 10% of DLBCLs, thus making it a rare variant of DLBCL. Cure rates for PMBCL with upfront regimens like DA-REPOCH exceed 90%. However, if there is a poor response to...
Autores principales: | Tomassetti, Sarah, Chen, Robert, Dandapani, Savita |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477766/ https://www.ncbi.nlm.nih.gov/pubmed/31040936 http://dx.doi.org/10.1177/2040620719841591 |
Ejemplares similares
-
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019) -
Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023) -
Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma
por: Li, Xin, et al.
Publicado: (2018) -
High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015) -
PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)